Conduit Pharmaceuticals announces 1-for-15 reverse stock split effective May 19, 2025

CDT Equity Inc.

1-for-15 reverse split effective May 19, 2025 at 5:00 p.m. ET; split-adjusted trading begins May 20 under ticker CDT.
Post-split outstanding shares reduced to approximately 755,900 from roughly 11.3 million pre-split.
No fractional shares issued; cash payment in lieu at closing price on May 19.
Par value unchanged at $0.0001; new CUSIP number 20678X 304; warrants and equity awards proportionally adjusted.
Stockholders approved reverse split at special meeting on May 5, 2025; board set exact ratio.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CDT Equity Inc.: Filed certificate of amendment to Second Amended and Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split (effective 2025-05-19).

Change: charter amendment
Effective: 2025-05-19

Exact text from the filing

On May 15, 2025, Conduit Pharmaceuticals Inc. (the “Company”) filed a certificate of amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effectuate a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock (“Common Stock”).

View on SEC.gov

Browse all governance changes →

CDT Equity Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-011183

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.